Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Richter Transformation: Results from the Phase 1/2 BRUIN Study

被引：24

作者：

Wierda, William G. ^{[1
]}

Lewis, David John ^{[2
]}

Ghia, Paolo ^{[3
,4
]}

Shah, Nirav N. ^{[5
]}

Coombs, Catherine C. ^{[6
]}

Cheah, Chan Y. ^{[7
,8
]}

Lamanna, Nicole ^{[9
]}

Rhodes, Joanna M. ^{[10
]}

Hoffmann, Marc ^{[11
]}

Ma, Shuo ^{[12
]}

Eyre, Toby A. ^{[13
]}

Munir, Talha ^{[14
]}

Patel, Manish R. ^{[15
]}

Alencar, Alvaro J. ^{[16
]}

Tam, Constantine S. ^{[17
,18
]}

Seymour, John F. ^{[19
]}

Jurczak, Wojciech ^{[20
]}

Lech-Maranda, Ewa ^{[21
]}

Roeker, Lindsey E. ^{[22
]}

Thompson, Philip A. ^{[1
]}

Abada, Paolo B. ^{[23
]}

Wang, Chunxiao ^{[24
]}

Nair, Binoj ^{[23
]}

Liu, Hui ^{[23
]}

Tsai, Donald E. ^{[23
]}

Mato, Anthony R. ^{[22
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[2] Plymouth Hosp NHS Trust, Derriford Hosp, Plymouth, Devon, England

[3] Univ Vita Salute San Raffaele, Milan, Italy

[4] IRCCS Osped San Raffaele, Milan, Italy

[5] Med Coll Wisconsin, Brookfield, WI USA

[6] Univ N Carolina, Chapel Hill, NC 27515 USA

[7] Linear Clin Res, Perth, WA, Australia

[8] Sir Charles Gairdner Hosp, Perth, WA, Australia

[9] Columbia Univ, Herbert Irving Comprehens Canc Ctr, Med Ctr, New York Presbyterian, New York, NY USA

[10] Northwell Hlth Canc Inst, New Hyde Pk, NY USA

[11] Univ Kansas, Ctr Canc, Kansas City, KS USA

[12] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Feinberg Sch Med, Chicago, IL USA

[13] Oxford Univ Hosp NHS Fdn Trust, Churchill Canc Ctr, Oxford, England

[14] St James Univ Hosp, Dept Haematol, Leeds, W Yorkshire, England

[15] Sarah Cannon Res Inst, Sarasota, FL USA

[16] Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA

[17] Royal Melbourne Hosp, Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[18] Univ Melbourne, Melbourne, Vic, Australia

[19] Univ Melbourne, Royal Melbourne Hosp, Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[20] Maria Sklodowska Curie Natl Res Inst Oncol, Krakow, Poland

[21] Inst Hematol & Transfus Med, Warsaw, Poland

[22] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[23] Loxo Lilly, Indianapolis, IN USA

[24] Eli Lilly & Co, Indianapolis, IN 46285 USA

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-157058

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 50 条

[1] Efficacy of pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in Richter transformation: Results from the phase 1/2 BRUIN study
Rhodes, Joanna
Lewis, David
Ghia, Paolo
Shah, Nirav N.
Coombs, Catherine C.
Cheah, Chan Y.
Woyach, Jennifer
Lamanna, Nicole
Hoffmann, Marc S.
Ma, Shuo
Eyre, Toby A.
Munir, Talha
Patel, Manish R.
Alencar, Alvaro J.
Tam, Constantine S.
Seymour, John F.
Jurczak, Wojciech
Lech-Maranda, Ewa
Roeker, Lindsey E.
Thompson, Philip A.
Abada, Paolo B.
Wang, Chunxiao
Nair, Binoj
Liu, Hui
Tsai, Donald E.
Mato, Anthony R.
Wierda, William G.
CANCER RESEARCH, 2023, 83 (08)
[2] Pirtobrutinib, a highly selective, non-covalent BTK inhibitor in Richter transformation: Results from the BRUIN study
Lewis, David John
Wierda, William G.
Ghia, Paolo
Shah, Nirav N.
Coombs, Catherine C.
Cheah, Chan Y.
Lamanna, Nicole
Rhodes, Joanna M.
Hoffmann, Marc S.
Ma, Shuo
Eyre, Toby A.
Munir, Talha
Patel, Manish R.
Alencar, Alvaro J.
Tam, Constantine S.
Seymour, John F.
Jurczak, Wojciech
Lech-Maranda, Ewa
Roeker, Lindsey E.
Thompson, Philip A.
Abada, Paolo B.
Wang, Chunxiao
Nair, Binoj
Liu, Hui
Tsai, Donald E.
Mato, Anthony R.
BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 : 107 - 108
[3] Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed / Refractory Waldenstrom Macroglobulinemia: Results from the Phase 1/2 BRUIN Study
Palomba, M. Lia
Patel, Manish R.
Eyre, Toby A.
Jurczak, Wojciech
Lewis, David John
Gastinne, Thomas
Ma, Shuo
Cohen, Jonathon B.
Patel, Krish
Brown, Jennifer R.
Scarfo, Lydia
Munir, Talha
Lech-Maranda, Ewa
Hoffmann, Marc
Ujjani, Chaitra S.
Fakhri, Bita
Wang, Michael L.
Izutsu, Koji
Nagai, Hirokazu
Tam, Constantine S.
Seymour, John F.
Rhodes, Joanna M.
Vose, Julie M.
McKinney, Matthew
Gerson, James N.
Barve, Minal A.
Kuss, Bryone J.
Koh, Youngil
Gao, Wei
Ruppert, Amy S.
Walgren, Richard A.
Tsai, Donald E.
Nair, Binoj
Bao, Katherine
Mato, Anthony R.
Cheah, Chan Y.
BLOOD, 2022, 140
[4] Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed/Refractory Follicular Lymphoma: Results from the Phase 1/2 BRUIN Study
Shah, Nirav N.
Zinzani, Pier Luigi
Wang, Michael L.
Nasta, Sunita D.
Lech-Maranda, Ewa
Ogawa, Yoshiaki
Fakhri, Bita
Kuss, Bryone
Miyashita, Kaname
Patel, Krish
Coombs, Catherine C.
Ma, Shuo
Patel, Manish
Barve, Minal A.
Tessoulin, Benoit
Stathis, Anastasios
Kim, Won Seog
Ennishi, Daisuke
Hashimoto, Daigo
Kojima, Kensuke
Zelenetz, Andrew D.
Cohen, Jonathon B.
Vose, Julie M.
Maddocks, Kami J.
Munir, Talha
Sun, Fangfang
Bian, Faith
Tsai, Donald E.
Abada, Paolo
Cheah, Chan Y.
BLOOD, 2023, 142
[5] Pirtobrutinib, A Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Previously Treated CLL/SLL: Updated Results from the Phase 1/2 BRUIN Study
Coombs, Catherine C.
Pagel, John M.
Shah, Nirav N.
Lamanna, Nicole
Munir, Talha
Lech-Maranda, Ewa
Eyre, Toby A.
Woyach, Jennifer A.
Wierda, William G.
Cheah, Chan Y.
Cohen, Jonathon B.
Roeker, Lindsey E.
Patel, Manish R.
Fakhri, Bita
Barve, Minal A.
Tam, Constantine S.
Lewis, David
Gerson, James N.
Alencar, Alvaro
Ujjani, Chaitra
Flinn, Ian
Sundaram, Suchitra
Ma, Shuo
Jagadeesh, Deepa
Rhodes, Joanna
Taylor, Justin
Abdel-Wahab, Omar
Ghia, Paolo
Schuster, Stephen J.
Wang, Denise
Nair, Binoj
Zhu, Edward
Tsai, Donald E.
Davids, Matthew S.
Brown, Jennifer R.
Jurczak, Wojciech
Mato, Anthony R.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S268 - S269
[6] Pirtobrutinib, A Highly Selective, Non-covalent (Reversible) BTK Inhibitor In Previously Treated CLL/SLL: Updated Results From The Phase 1/2 BRUIN Study
Mato, Anthony
Pagel, John
Coombs, Catherine
Shah, Nirav
Lamanna, Nicole
Munir, Talha
Lech-Maranda, Ewa
Eyre, Toby
Woyach, Jennifer
Wierda, William
Cheah, Chan
Cohen, Johnathan
Roeker, Lindsey
Patel, Manish
Fakhri, Bita
Barve, Minal
Tam, Constantine
Lewis, David
Gerson, James
Alencar, Alvaro
Ujjani, Chaitra
Flinn, Ian
Sundaram, Suchitra
Ma, Shuo
Jagadeesh, Deepa
Rhodes, Joanna
Taylor, Justin
Abdel-Wahab, Omar
Ghia, Paolo
Schuster, Stephen
Wang, Denise
Nair, Binoj
Zhu, Edward
Tsai, Donald
Davids, Matthew
Brown, Jennifer
Jurczak, Wojciech
BRITISH JOURNAL OF HAEMATOLOGY, 2022, 197 : 97 - 101
[7] Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed / Refractory Marginal Zone Lymphoma: Results from Phase 1/2 BRUIN Study
Patel, Krish
Vose, Julie M.
Nasta, Sunita D.
Brown, Jennifer R.
Maddocks, Kami J.
Woyach, Jennifer A.
Shah, Nirav N.
Fakhri, Bita
Tessoulin, Benoit
Ma, Shuo
Jagadeesh, Deepa
Lech-Maranda, Ewa
Coombs, Catherine C.
Patel, Manish
Rhodes, Joanna M.
Ujjani, Chaitra S.
Hoffmann, Marc S.
Cheah, Chan Y.
Munir, Talha
Lewis, David
Scarfo, Lydia
Eyre, Toby A.
Alencar, Alvaro J.
Cohen, Jonathon B.
Zelenetz, Andrew D.
Tsai, Donald E.
Li, Mei
Bian, Faith
Abada, Paolo
Zinzani, Pier Luigi
BLOOD, 2023, 142
[8] Pirtobrutinib, A Highly Selective, Non-covalent (Reversible) BTK Inhibitor In Previously Treated Mantle Cell Lymphoma: Updated Results From The Phase 1/2 BRUIN Study
Wang, Michael
Shah, Nirav
Alencar, Alvaro
Gerson, James
Patel, Manish
Fakhri, Bita
Jurczak, Wojciech
Tan, Xuan
Lewis, Katharine
Fenske, Timothy
Coombs, Catherine
Flinn, Ian
Lewis, David
Le Gouill, Steven
Palomba, M. Lia
Woyach, Jennifer
Pagel, John
Lamanna, Nicole
Cohen, Johnathon
Barve, Minal
Ghia, Paolo
Eyre, Toby
Zinzani, Pier Luigi
Ujjani, Chaitra
Koh, Youngil
Izutsu, Koji
Lech-Maranda, Ewa
Tam, Constantine
Sundaram, Suchitra
Yin, Ming
Nair, Binoj
Tsai, Donald
Balbas, Minna
Mato, Anthony
Cheah, Chan
BRITISH JOURNAL OF HAEMATOLOGY, 2022, 197 : 101 - 104
[9] Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study
Wierda, William G.
Shah, Nirav N.
Cheah, Chan Y.
Lewis, David
Hoffmann, Marc S.
Coombs, Catherine C.
Lamanna, Nicole
Ma, Shuo
Jagadeesh, Deepa
Munir, Talha
Wang, Yucai
Eyre, Toby A.
Rhodes, Joanna M.
McKinney, Matthew
Lech-Maranda, Ewa
Tam, Constantine S.
Jurczak, Wojciech
Izutsu, Koji
Alencar, Alvaro J.
Patel, Manish R.
Seymour, John F.
Woyach, Jennifer A.
Thompson, Philip A.
Abada, Paolo B.
Ho, Caleb
McNeely, Samuel C.
Marella, Narasimha
Nguyen, Bastien
Wang, Chunxiao
Ruppert, Amy S.
Nair, Binoj
Liu, Hui
Tsai, Donald E.
Roeker, Lindsey E.
Ghia, Paolo
LANCET HAEMATOLOGY, 2024, 11 (09): : e682 - e692
[10] Pirtobrutinib; A Next Generation; Highly Selective; Non-covalent BTK Inhibitor In Previously Treated CLL/SLL: Updated Results From The Phase 1/2 BRUIN Study
Pagel, John M.
Coombs, Catherine C.
Shah, Nirav N.
Lamanna, Nicole
Lech-Maranda, Ewa
Eyre, Toby A.
Woyach, Jennifer A.
Weirda, William G.
Cheah, Chan Y.
Roeker, Lindsey E.
Patel, Manish R.
Fakhri, Bita
Barve, Minal A.
Tam, Constantine
Lewis, David
Gerson, James N.
Alencar, Alvaro J.
Ghia, Paolo
Schuster, Stephen J.
Davids, Matthew S.
Brown, Jennifer R.
Jurczak, Wojciech
Mato, Anthony R.
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 168 - 169

← 1 2 3 4 5 →